financetom
Business
financetom
/
Business
/
Qualcomm Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Qualcomm Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
May 25, 2025 10:54 PM

QUALCOMM Incorporated ( QCOM ) will release earnings results for the second quarter, after the closing bell on Wednesday, April 30.

Analysts expect the Santa Monica, California-based company to report quarterly earnings at 4 cents per share, up from 3 cents per share in the year-ago period. Qualcomm ( QCOM ) projects to report quarterly revenue at $1.35 billion, compared to $1.19 billion a year earlier, according to data from Benzinga Pro.

Qualcomm ( QCOM ), earlier during the month, expanded its generative AI capabilities with the acquisition of VinAI Division.

Qualcommshares fell 0.5% to close at $146.88 on Tuesday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.

JP Morgan analyst Samik Chatterjee reinstated an Overweight rating with a price target of $185 on April 29, 2025. This analyst has an accuracy rate of 69%.

Citigroup analyst Christopher Danely maintained a Neutral rating and slashed the price target from $185 to $145 on April 11, 2025. This analyst has an accuracy rate of 77%.

Evercore ISI Group analyst Mark Lipacis maintained an In-Line rating and slashed the price target from $199 to $179 on Feb. 6, 2025. This analyst has an accuracy rate of 71%.

Piper Sandler analyst Harsh Kumar maintained an Overweight rating and cut the price target from $205 to $190 on Feb. 6, 2025. This analyst has an accuracy rate of 79%.

Rosenblatt analyst Kevin Cassidy maintained a Buy rating with a price target of $250 on Feb. 6, 2025. This analyst has an accuracy rate of 66%.

Considering buying QCOM stock? Here’s what analysts think:

Read This Next:

Top 3 Industrials Stocks Which Could Rescue Your Portfolio In Q2

Photo via Shutterstock

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Ventyx Biosciences Shares Fall After Tier 2 Exploratory Biomarkers Remain Stable in Parkinson's Study
Ventyx Biosciences Shares Fall After Tier 2 Exploratory Biomarkers Remain Stable in Parkinson's Study
Jun 17, 2025
10:42 AM EDT, 06/17/2025 (MT Newswires) -- Ventyx Biosciences ( VTYX ) shares were down 17% in recent trading Tuesday after topline data from its phase 2a study of its drug candidate VTX3232 in patients with early-stage Parkinson's disease showed Tier 2 exploratory brain-related biomarkers remained unchanged or fluctuated within normal levels. The study achieved its primary safety and tolerability...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Capricor Therapeutics' Deramiocel Wins FDA Orphan Drug Designation for Becker Muscular Dystrophy
Capricor Therapeutics' Deramiocel Wins FDA Orphan Drug Designation for Becker Muscular Dystrophy
Jun 17, 2025
10:41 AM EDT, 06/17/2025 (MT Newswires) -- Capricor Therapeutics ( CAPR ) said the US Food and Drug Administration granted an orphan drug designation to its Deramiocel therapy candidate to treat Becker Muscular Dystrophy, a neuromuscular disorder. The biologics license application for Deramiocel to treat Duchenne Muscular Dystrophy remains under priority review with a target action date of Aug. 31,...
John Wiley & Sons Affirms Revenue Outlook After Mixed Quarterly Results
John Wiley & Sons Affirms Revenue Outlook After Mixed Quarterly Results
Jun 17, 2025
10:41 AM EDT, 06/17/2025 (MT Newswires) -- John Wiley & Sons ( WLY ) shares jumped intraday Tuesday as the company maintained its fiscal 2026 revenue outlook after posting mixed fourth-quarter results. The publishing company said it continues to expect adjusted revenue growth in the low- to mid-single digit range from fiscal 2025's $1.66 billion, which was up 3% at...
Copyright 2023-2026 - www.financetom.com All Rights Reserved